BIOGEN has announced that Zinbryta (daclizumab) is available on the Pharmaceutical Benefits Scheme (PBS) from today for the treatment of relapsing-remitting multiple sclerosis
It is currently listed on the ARTG "for the treatment of relapsing forms of MS, to delay the progression of physical disability and to reduce the frequency of relapse."
Zinbryta is a once-monthly self-administered injection which works by stopping the body's immune system from damaging the brain and spinal cord, Biogen has said.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 May 17